Severe pretreatment hepatic steatosis influences response to direct acting antiviral therapy for chronic hepatitis C in a real world setting

Clin Res Hepatol Gastroenterol. 2020 Apr;44(2):e35-e37. doi: 10.1016/j.clinre.2019.05.004. Epub 2019 Jun 14.

Authors

Paul A Gomez¹, Kelly M Zucker¹, Jean Chang², Michael W Rowley¹, Anil B Seetharam³

Affiliations

¹ Internal Medicine, University of Arizona College of Medicine Phoenix, Banner University Medical Center Phoenix, Phoenix, AZ, USA.
² University of Washington School of Medicine, Seattle, WA, USA.
³ University of Arizona College of Medicine Phoenix, Transplant and Advanced Liver Disease Center, Banner University Medical Center Phoenix, Phoenix, AZ, USA. Electronic address: [email protected].

PMID: 31208924
DOI: 10.1016/j.clinre.2019.05.004

No abstract available

Keywords: Direct acting antiviral therapy; Hepatic steatosis; Hepatitis C virus.

Publication types

Letter

MeSH terms

Fatty Liver / complications*
Female
Hepatitis C, Chronic / complications*
Hepatitis C, Chronic / drug therapy*
Humans
Male
Severity of Illness Index
Treatment Outcome